Precision medicine represents a paradigm shift in healthcare, emphasizing individualized approaches to disease prevention, diagnosis, and treatment based on a patient’s genetic, proteomic, and immunologic profile. In the field of oncology, this paradigm has gained traction, particularly with the integration of immunotherapeutic modalities. Among the most promising advancements are therapeutic cancer vaccines, which harness the body’s immune system to fight tumors more effectively. This mini-review highlights recent developments in therapeutic vaccine engineering. It also discusses key barriers to clinical translation and summarizes findings from contemporary human clinical trials evaluating personalized cancer vaccines. In addition, it evaluates the growing potential of these therapies to redefine cancer treatment.

The results of a clinical trial involving the University of Cincinnati, recently published in The New England Journal of Medicine, show people failing HIV treatments with oral medications were able to be treated successfully using injections.

With funding from the National Institute on Aging, George Mason health economist Jeah Jung will evaluate how Medicare Advantage’s new non-medical benefits like food and transportation impact health care use and patient outcomes.

Scientists at the University of California, Irvine’s School of Pharmacy & Pharmaceutical Sciences have discovered how muscle stem cells “flip a switch” to rebuild damaged muscle – a finding that could help address muscle loss linked to aging, injury and widely used weight-loss medications.

The School of Dentistry at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, received a major National Institutes of Health grant renewal to examine the biological mechanisms of temporomandibular joint (TMJ) disorder, aimed at developing the first targeted, non-opioid treatment for chronic pain.